News

search close

Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms

Read more

Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Read more

Relmada Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference

Read more

Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder

Read more

Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations

Read more

Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs

Read more

Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety

Read more

Relmada Therapeutics Strengthens Scientific Leadership Team with the Appointment of Judy Caron, Ph.D., as Vice President of Drug Development

Read more

Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development

Read more

Relmada Therapeutics to Present at 9th Annual SVB Leerink Global Healthcare Conference

Read more